-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Initiates Coverage On Mineralys Therapeutics with Neutral Rating, Announces Price Target of $29

Benzinga·10/12/2026 13:33:19
Listen to the news
UBS analyst Alice Nettleton initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Neutral rating and announces Price Target of $29.